Close Menu
    Facebook X (Twitter) Instagram
    TRENDING :
    • Wendy’s store closures hit close to 100 locations in franchisee downfall: See the latest list
    • Taco Dowler Leaves Montana State With Historic Receiving Records
    • 7 Best Practices for Vendor Relationship Management
    • Mike Evans May Avoid Limited Snap Count Sunday
    • John Wayne’s $11,000 Western Turns 92 – and It Was Shot in Under a Week
    • South County Rolls to Ninth Straight Win as Mona Shores Hits 12
    • Tom Jackson, Broncos Legend and ESPN Voice, Dies at 75
    • The ‘Worst James Bond Movie’ Was Panned as a ‘Trainwreck’ 24 Years Ago
    Populist Bulletin
    • Home
    • US Politics
    • World Politics
    • Economy
    • Business
    • Headline News
    Populist Bulletin
    Home»Business»Hims & Hers stock price is surging today. A surprising rumor about Novo Nordisk is the reason why
    Business 4 Mins Read

    Hims & Hers stock price is surging today. A surprising rumor about Novo Nordisk is the reason why

    Business 4 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email Copy Link
    Follow Us
    Google News Flipboard
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Shares in Hims & Hers Health (NYSE: HIMS) are soaring this morning after an unconfirmed report that the telehealth company is entering into a deal with Novo Nordisk A/S (NYSE: NVO) to sell its popular GLP-1 weight-loss drugs, including Wegovy.

    The rumored deal is as surprising as Hims & Hers’s surging stock price this morning, especially considering that just last month, Novo was threatening to sue the telehealth provider. Here’s what you need to know.

    What’s happened?

    Late on Friday, Bloomberg reported that Hims & Hers has reached an agreement with the Danish drugmaker Novo Nordisk to sell Novo’s weight-loss drugs, including the popular GLP-1 pill Wegovy.

    According to the publication, which cited an anonymous source, the news could be publicly announced as soon as today.

    Fast Company has reached out to Hims & Hers and Novo Nordisk for comment.

    The reported partnership between the two firms would be a stunning reversal in their relationship, which, as recently as last month, was highly acrimonious.

    Their feud stems from an announcement in early February that Hims & Hers would sell a compounded version of Novo’s Wegovy weight-loss pill at a third of the price Novo sells it for.

    Hims & Hers said its compounded version would sell for $49 per month, before rising to $99. Novo sells its Wegovy for $149 per month.

    While Novo Nordisk owns the patent to Wegovy, Hims & Hers sought to get around this by offering not a generic version of the drug but a compounded one.

    Compounded drugs are ones that are nearly identical copies of a drug. The U.S. Food and Drug Administration (FDA) sometimes allows pharmacists to create compounded versions of drugs when the name-brand version is a short supply, as was the case with many GLP-1 drugs in 2024 and 2025.

    However, by the middle of 2025, the GLP-1 shortage was largely resolved, and compounding pharmacies were ordered to stop making their compounded versions of the drugs. 

    Regardless, in February, Hims & Hers announced it would sell its own GLP-1 drug made from semaglutide, the same active ingredient in Wegovy.

    This led to fierce backlash from Novo Nordisk, which threatened to sue Hims & Hers. The FDA similarly threatened to take action against the telehealth company.

    As a result, shortly after announcing its Wegovy knockoff, Hims & Hers said it would no longer release its own version.

    Given the contentious nature of this ordeal, few thought Hims & Hers and Novo Nordisk would ever play nice together in the future. But according to Bloomberg’s report, that’s just what the two companies are planning to do now.

    Why is Novo playing nice with Hims now?

    While Novo and Hims & Hers did briefly have an agreement to sell the Danish company’s branded Wegovy on its platform in 2025, that deal fell through in less than two months.

    Few expected the two companies to work together again. Yet, if Bloomberg’s report is accurate, they now are. But why?

    The most likely reason is that Novo Nordisk wants to expand the market for Wegovy, and the fastest way to do that is to have the medication available for purchase in as many places and on as many platforms as possible.

    Wegovy isn’t the only weight-loss drug available, and it risks being overshadowed by the accelerating adoption of other drugs. 

    As Hims & Hers becomes increasingly popular among consumers as a source for their medications, Novo has likely concluded that the platform’s rising popularity is worth setting aside old hostilities to help Wegovy capture as much market share as possible.

    How are HIMS and NVO share prices reacting?

    The share price of Hims & Hers is skyrocketing on the report that the telehealth firm has reached a new deal with Novo Nordisk. As of the time of this writing, in premarket trading, HIMS stock is up nearly 45% to $22.77.

    On Friday, HIMS stock closed at $15.74.

    Unfortunately for Novo Nordisk investors, the rumored partnership has had a relatively negligible impact on NVO stock. As of the time of this writing, NVO shares are up about half a percent to $38.79 in premarket.

    Before this morning’s premarket boost, HIMS stock was down over 51% year to date. This means that if the HIMS gains hold, the stock could earn back most of its 2026 losses in just one trading session.

    As for Novo Nordisk, the company’s stock price is also down significantly year to date. As of Friday’s close at $38.58, NVO shares had lost nearly 25% of their value since 2026 began.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Wendy’s store closures hit close to 100 locations in franchisee downfall: See the latest list

    November 22, 2026

    7 Best Practices for Vendor Relationship Management

    November 22, 2026

    CrowdStrike CEO: Companies are choosing between getting hacked and shutting down

    November 22, 2026
    Top News
    Business 7 Mins Read

    Is it even possible to decentralize social networking?

    Business 7 Mins Read

    Hello again, and welcome back to Fast Company’s Plugged In. On March 9, Jay Graber…

    Scott Jennings Uses Letitia James’ Own Words Against Her: ‘I Don’t Think the American People Are Going to Have Too Much Sympathy’ | The Gateway Pundit

    October 11, 2025

    The busiest commuter train system in the U.S. could be headed for an imminent shutdown

    May 16, 2026

    I auditioned 12 AI agents to be my chief of staff. Here’s how they compared

    November 2, 2026
    Top Trending
    Business 3 Mins Read

    Wendy’s store closures hit close to 100 locations in franchisee downfall: See the latest list

    Business 3 Mins Read

    The owner of a dwindling empire of Wendy’s restaurants on Friday disclosed…

    World Politics 1 Min Read

    Taco Dowler Leaves Montana State With Historic Receiving Records

    World Politics 1 Min Read

    Montana State receiver Taco Dowler is wrapping up his college career with…

    Business 10 Mins Read

    7 Best Practices for Vendor Relationship Management

    Business 10 Mins Read

    Managing vendor relationships effectively can greatly impact your business’s success. Start by…

    Categories
    • Business
    • Economy
    • Headline News
    • Top News
    • US Politics
    • World Politics
    About us

    The Populist Bulletin was founded with a fervent commitment to inform, inspire, empower and spark meaningful conversations about the economy, business, politics, government accountability, globalization, and the preservation of American cultural heritage.

    We are devoted to delivering straightforward, unfiltered, compelling, relatable stories that resonate with the majority of the American public, while boldly challenging false mainstream narratives that seem to only serve entrenched elitists, and foreign interests.

    Top Picks

    Wendy’s store closures hit close to 100 locations in franchisee downfall: See the latest list

    November 22, 2026

    Taco Dowler Leaves Montana State With Historic Receiving Records

    November 22, 2026

    7 Best Practices for Vendor Relationship Management

    November 22, 2026
    Categories
    • Business
    • Economy
    • Headline News
    • Top News
    • US Politics
    • World Politics
    Copyright © 2025 Populist Bulletin. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.